1.09
0.91%
-0.01
Cytomx Therapeutics Inc Borsa (CTMX) Ultime notizie
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Position Raised by Fmr LLC - Defense World
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
CytomX Therapeutics (NASDAQ:CTMX) Stock Crosses Below 200 Day Moving AverageHere's What Happened - MarketBeat
SNY's Tolebrutinib Gets FDA Breakthrough Therapy Tag for nrSPMS - MSN
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Bounce 26% But Its Business Still Trails The Industry - Simply Wall St
CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
CytomX Therapeutics' SWOT analysis: biotech stock's solid tumor focus By Investing.com - Investing.com Canada
Janus Henderson Group PLC Trims Stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - MarketBeat
Recent uptick might appease CytomX Therapeutics, Inc. (NASDAQ:CTMX) institutional owners after losing 21% over the past year - Simply Wall St
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 21.7% in November - MarketBeat
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives $5.77 Consensus Price Target from Brokerages - Defense World
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference - The Manila Times
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives $5.77 Consensus Price Target from Analysts - MarketBeat
Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround - Yahoo Finance
CytomX stock touches 52-week low at $0.98 amid market challenges - Investing.com India
Biotechnology Value Fund L P Increases Stake in CytomX Therapeutics Inc - GuruFocus.com
TANG CAPITAL MANAGEMENT LLC Acquires Shares in CytomX Therapeuti - GuruFocus.com
Analysis of JANUS HENDERSON GROUP PLC's Recent Transaction in Cy - GuruFocus.com
HC Wainwright Has Bullish Estimate for CTMX FY2024 Earnings - Defense World
HC Wainwright Has Positive Outlook for CTMX FY2024 Earnings - MarketBeat
CytomX Therapeutics' SWOT analysis: biotech stock's potential in cancer treatment - Investing.com UK
CytomX Therapeutics (NASDAQ:CTMX) Earns "Neutral" Rating from HC Wainwright - MarketBeat
CytomX Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
CytomX Therapeutics (NASDAQ:CTMX) Stock Price Crosses Below 50 Day Moving AverageTime to Sell? - MarketBeat
CytomX Therapeutics Inc earnings beat by $0.24, revenue topped estimates - Investing.com Australia
CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates - MSN
CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: - GuruFocus.com
CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance
CytomX Therapeutics: Q3 Earnings Snapshot - Darien Times
CytomX Therapeutics Reports Q3 Progress and Growth - TipRanks
CytomX stock touches 52-week low at $0.98 amid market shifts - Investing.com India
CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q3 202 - GuruFocus.com
Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q3 2024 Result - Yahoo Finance
Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $5.77 - Defense World
CytomX Therapeutics (CTMX) Set to Announce Earnings on Thursday - MarketBeat
CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 - The Manila Times
Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) PT at $5.77 - MarketBeat
Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues - Simply Wall St
CytomX stock plunges to 52-week low at $1.03 amid market challenges - Investing.com India
CytomX Therapeutics, Inc.($CTMX) - substack.com
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 10.5% in September - MarketBeat
CytomX Therapeutics Inc (CTMX) rating upgrades by Piper Sandler - Knox Daily
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):